Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report
Abstract Introduction Bullous pemphigoid (BP) is a rare but clinically significant cutaneous immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. It is most often described during treatment of melanoma, lung cancer, and renal cell carcinoma, whereas reports in gynecologic oncology, and spec...